233 related articles for article (PubMed ID: 37489050)
1. Inhibitors of phosphoinositide 3-kinase (PI3K) and phosphoinositide 3-kinase-related protein kinase family (PIKK).
Huang X; You L; Nepovimova E; Psotka M; Malinak D; Valko M; Sivak L; Korabecny J; Heger Z; Adam V; Wu Q; Kuca K
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2237209. PubMed ID: 37489050
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of the PI3K/AKT/mTOR pathway in human malignancies; trend of current clinical trials.
Davoodi-Moghaddam Z; Jafari-Raddani F; Delshad M; Pourbagheri-Sigaroodi A; Bashash D
J Cancer Res Clin Oncol; 2023 Nov; 149(16):15293-15310. PubMed ID: 37594532
[TBL] [Abstract][Full Text] [Related]
3. Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers.
Shan KS; Bonano-Rios A; Theik NWY; Hussein A; Blaya M
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396649
[TBL] [Abstract][Full Text] [Related]
4. PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer.
Zhu K; Wu Y; He P; Fan Y; Zhong X; Zheng H; Luo T
Cells; 2022 Aug; 11(16):. PubMed ID: 36010585
[TBL] [Abstract][Full Text] [Related]
5. The PI3K/AKT/mTOR signaling pathway in breast cancer: Review of clinical trials and latest advances.
Khorasani ABS; Hafezi N; Sanaei MJ; Jafari-Raddani F; Pourbagheri-Sigaroodi A; Bashash D
Cell Biochem Funct; 2024 Apr; 42(3):e3998. PubMed ID: 38561964
[TBL] [Abstract][Full Text] [Related]
6. [Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer].
; ; ;
Zhonghua Zhong Liu Za Zhi; 2022 Jul; 44(7):673-692. PubMed ID: 35880333
[TBL] [Abstract][Full Text] [Related]
7. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside.
Alzahrani AS
Semin Cancer Biol; 2019 Dec; 59():125-132. PubMed ID: 31323288
[TBL] [Abstract][Full Text] [Related]
8. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.
Ediriweera MK; Tennekoon KH; Samarakoon SR
Semin Cancer Biol; 2019 Dec; 59():147-160. PubMed ID: 31128298
[TBL] [Abstract][Full Text] [Related]
9. Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTOR pathway in combination with TKIs: a review.
Singh P; Kumar V; Gupta SK; Kumari G; Verma M
Med Oncol; 2021 Jan; 38(1):10. PubMed ID: 33452624
[TBL] [Abstract][Full Text] [Related]
10. Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer.
Lim HJ; Crowe P; Yang JL
J Cancer Res Clin Oncol; 2015 Apr; 141(4):671-89. PubMed ID: 25146530
[TBL] [Abstract][Full Text] [Related]
11. Elucidation of the Role of the Epigenetic Regulatory Mechanisms of PI3K/Akt/mTOR Signaling Pathway in Human Malignancies.
Mohite R; Doshi G
Curr Cancer Drug Targets; 2024; 24(3):231-244. PubMed ID: 37526459
[TBL] [Abstract][Full Text] [Related]
12. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.
Martelli AM; Evangelisti C; Chiarini F; McCubrey JA
Oncotarget; 2010 Jun; 1(2):89-103. PubMed ID: 20671809
[TBL] [Abstract][Full Text] [Related]
13. Achieving cancer cell death with PI3K/mTOR-targeted therapies.
Yea SS; Fruman DA
Ann N Y Acad Sci; 2013 Mar; 1280(1):15-8. PubMed ID: 23551096
[TBL] [Abstract][Full Text] [Related]
14. The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era.
Liu ST; Hui G; Mathis C; Chamie K; Pantuck AJ; Drakaki A
Clin Genitourin Cancer; 2018 Apr; 16(2):e269-e276. PubMed ID: 29199023
[TBL] [Abstract][Full Text] [Related]
15. PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro.
Wu X; Yu J; Yan J; Dai J; Si L; Chi Z; Sheng X; Cui C; Ma M; Tang H; Xu T; Yu H; Kong Y; Guo J
Cancer Biol Ther; 2018 Jul; 19(7):584-589. PubMed ID: 29708815
[TBL] [Abstract][Full Text] [Related]
16. PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.
Wu P; Hu YZ
Curr Med Chem; 2010; 17(35):4326-41. PubMed ID: 20939811
[TBL] [Abstract][Full Text] [Related]
17. Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK.
Tran KB; Kolekar S; Jabed A; Jaynes P; Shih JH; Wang Q; Flanagan JU; Rewcastle GW; Baguley BC; Shepherd PR
BMC Cancer; 2021 Feb; 21(1):136. PubMed ID: 33549048
[TBL] [Abstract][Full Text] [Related]
18. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J; Janku F
Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
[TBL] [Abstract][Full Text] [Related]
19. Targeting PI3K in cancer: mechanisms and advances in clinical trials.
Yang J; Nie J; Ma X; Wei Y; Peng Y; Wei X
Mol Cancer; 2019 Feb; 18(1):26. PubMed ID: 30782187
[TBL] [Abstract][Full Text] [Related]
20. Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer.
Yu L; Wei J; Liu P
Semin Cancer Biol; 2022 Oct; 85():69-94. PubMed ID: 34175443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
